Folic acid supplementation and risk of colorectal neoplasia during long-term follow-up of a randomized clinical trial.
Am J Clin Nutr
; 110(4): 903-911, 2019 10 01.
Article
em En
| MEDLINE
| ID: mdl-31401653
ABSTRACT
BACKGROUND:
The Aspirin/Folate Polyp Prevention Study previously found folic acid increased risk of advanced and multiple colorectal adenomas during a surveillance colonoscopy interval starting about 3 y after randomization.OBJECTIVE:
We conducted secondary analyses to evaluate folic acid effects with additional follow-up after treatment was stopped.METHODS:
In total, 1021 participants recently diagnosed with colorectal adenomas were randomly assigned to 1 mg/d of folic acid (n = 516) or placebo (n = 505), with or without aspirin, beginning 6 July 1994. The original 3-y treatment period was extended into a subsequent colonoscopy interval, but eventually stopped prematurely on 1 October 2004. With additional post-treatment follow-up, a total of 663 participants who extended treatment completed a second colonoscopic surveillance interval after the initial 3-y follow-up. In addition, 490 participants provided information regarding a subsequent surveillance colonoscopy occurring before completion of follow-up on 31 May 2012, including 325 who had agreed to extended treatment. Study endpoints included conventional adenomas, sessile serrated adenomas/polyps (SSA/Ps), or colorectal cancer, and RRs with 95% CIs were adjusted for baseline characteristics associated with availability of follow-up.RESULTS:
Among those who extended treatment, any colorectal neoplasia was found in 118 (36%) participants assigned to placebo and 146 (43%) assigned to folic acid during the second surveillance interval (RR 1.21; 95% CI 0.99, 1.47; P = 0.06). Increased risk of SSA/P with extended folic acid supplementation was statistically significant during the second surveillance interval (RR 1.94; 95% CI 1.02, 3.68; P = 0.04). There was no evidence of post-treatment effects for any colorectal neoplasia (RR 1.01; 95% CI 0.80, 1.28; P = 0.94), and the post-treatment effect for SSA/P was no longer statistically significant (RR 1.38; 95% CI 0.59, 3.19; P = 0.46).CONCLUSIONS:
Delayed treatment effects were not observed, but folic acid may increase SSA/P risk. This trial was registered at clinicaltrials.gov as NCT00272324.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Suplementos Nutricionais
/
Ácido Fólico
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
Idioma:
En
Revista:
Am J Clin Nutr
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos